MONOPHARMAPharmaceuticals
Mono Pharmacre Ltd — Profit & Loss Statement
₹11.15
-4.70%
Mono Pharmacre Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| EBIT | 8.49 Cr | 6.31 Cr | 3.00 Cr | 1.21 Cr | — |
| EBITDA | 8.62 Cr | 6.42 Cr | 3.10 Cr | 1.31 Cr | — |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.30 | 0.24 | 0.26 | 0.36 | — |
| Normalized EBITDA | 8.62 Cr | 6.42 Cr | 3.10 Cr | 1.31 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 3.09 Cr | 2.45 Cr | 1.23 Cr | 0.35 Cr | — |
| Reconciled Depreciation | 0.13 Cr | 0.12 Cr | 0.05 Cr | 0.11 Cr | — |
| Reconciled Cost Of Revenue | 152.32 Cr | 110.68 Cr | 53.34 Cr | 34.69 Cr | — |
| Net Interest Income | -4.03 Cr | -3.08 Cr | -1.32 Cr | -0.73 Cr | — |
| Interest Expense | 4.03 Cr | 3.08 Cr | 1.32 Cr | 0.65 Cr | — |
| Normalized Income | 3.09 Cr | 2.45 Cr | 1.23 Cr | 0.35 Cr | — |
| Net Income From Continuing And Discontinued Operation | 3.09 Cr | 2.45 Cr | 1.23 Cr | 0.35 Cr | — |
| Total Expenses | 160.84 Cr | 116.13 Cr | 55.61 Cr | 35.81 Cr | — |
| Diluted NI Availto Com Stockholders | 3.09 Cr | 2.45 Cr | 1.23 Cr | 0.35 Cr | — |
| Net Income Common Stockholders | 3.09 Cr | 2.45 Cr | 1.23 Cr | 0.35 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 3.09 Cr | 2.45 Cr | 1.23 Cr | 0.35 Cr | — |
| Minority Interests | -0.02 Cr | -75000.00 | -17000.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 3.11 Cr | 2.46 Cr | 1.23 Cr | 0.35 Cr | — |
| Net Income Continuous Operations | 3.11 Cr | 2.46 Cr | 1.23 Cr | 0.35 Cr | — |
| Tax Provision | 1.36 Cr | 0.77 Cr | 0.44 Cr | 0.20 Cr | — |
| Pretax Income | 4.46 Cr | 3.23 Cr | 1.68 Cr | 0.55 Cr | — |
| Other Non Operating Income Expenses | 0.98 Cr | 0.10 Cr | 0.14 Cr | 0.11 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | -4.03 Cr | -3.08 Cr | -1.32 Cr | -0.73 Cr | — |
| Interest Expense Non Operating | 4.03 Cr | 3.08 Cr | 1.32 Cr | 0.65 Cr | — |
| Operating Income | 7.51 Cr | 6.21 Cr | 2.86 Cr | 1.17 Cr | — |
| Operating Expense | 8.52 Cr | 5.45 Cr | 2.28 Cr | 1.12 Cr | — |
| Other Operating Expenses | 4.60 Cr | 1.82 Cr | 1.07 Cr | 0.26 Cr | — |
| Depreciation And Amortization In Income Statement | 0.13 Cr | 0.12 Cr | 0.10 Cr | 0.11 Cr | — |
| Depreciation Income Statement | 0.13 Cr | 0.12 Cr | 0.10 Cr | 0.11 Cr | — |
| Gross Profit | 16.03 Cr | 11.66 Cr | 5.14 Cr | 2.29 Cr | — |
| Cost Of Revenue | 152.32 Cr | 110.68 Cr | 53.34 Cr | 34.69 Cr | — |
| Total Revenue | 168.34 Cr | 122.34 Cr | 58.48 Cr | 36.98 Cr | — |
| Operating Revenue | 168.34 Cr | 122.34 Cr | 58.48 Cr | 36.98 Cr | — |
| Interest Income | — | 0.03 Cr | 26000.00 | 93000.00 | 0.00 |
| Rent Expense Supplemental | — | 0.16 Cr | 0.11 Cr | 0.09 Cr | 0.06 Cr |
| Diluted Average Shares | — | 1.55 Cr | 1.77 Cr | 1.77 Cr | 1.77 Cr |
| Basic Average Shares | — | 1.55 Cr | 1.77 Cr | 1.77 Cr | 1.77 Cr |
| Diluted EPS | — | 1.58 | 0.70 | 0.20 | 0.05 |
| Basic EPS | — | 1.58 | 0.70 | 0.20 | 0.05 |
| Write Off | — | 0.19 Cr | 0.00 | 0.00 | 0.00 |
| Total Other Finance Cost | — | 0.24 Cr | 0.11 Cr | 0.09 Cr | 0.02 Cr |
| Interest Income Non Operating | — | 0.03 Cr | 26000.00 | 93000.00 | 0.00 |
| Selling General And Administration | — | 0.69 Cr | 0.19 Cr | 0.04 Cr | 0.03 Cr |
| Selling And Marketing Expense | — | 0.43 Cr | 8000.00 | 0.00 | 64000.00 |
| General And Administrative Expense | — | 0.26 Cr | 0.19 Cr | 0.04 Cr | 0.02 Cr |
| Rent And Landing Fees | — | 0.16 Cr | 0.11 Cr | 0.09 Cr | 0.06 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mono Pharmacre Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.